ClinicalTrials.gg
CompletedNCT07150884LACTOGAINUpdated Oct 8, 2026

Lactase-Assisted Control Trial On Weight GAin in INfants.

An interventional study of Lactase in Prematurity, sponsored by Aristotle University Of Thessaloniki. Completed at 1 site in Greece. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Aristotle University Of Thessaloniki · Not applicable, Interventional, and Other

Updated Oct 8, 2026Now CompletedEligibility revised+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies in Premature Birth with a site in Greece — 7 open to participants now, 8 under way, none of them phase 3. Premature Birth · Greece.

Enrollment
7th of 13
100 · median 100
Started
2025
with 2 others
No phase
9 of 16
4 open now
Registered
15th of 16
by date
Lead sponsor
2 of 16
Aristotle University Of Thessaloniki

Among the 16 studies in Premature Birth with a site in Greece, this one is the 7th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2025, is one of 9 with no phase, and was the 15th registered.

Premature Birth

2,556 studies on the registry are indexed under Premature Birth; 503 are open to participants now.

Browse Premature Birth studies →

Open to participants now

7 of the 16 studies in Premature Birth with a site in Greece are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 317 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 225 (71%) stop at 75 or younger; 242 take children under 18; 104 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Premature Birth with a site in Greece, or all of them as a file.
02

Study summary

Lactose, a disaccharide that includes the monosaccharides glucose and galactose, is the main carbohydrate found exclusively in mammalian milk. Lactase is found in the intestinal mucosa and is located at the ends of the villi, while it is a factor of maximum clinical importance in milk tolerance and in the occurrence of diarrheal disease. Developmental lactase deficiency is defined as the relative lactase deficiency observed in premature newborns less than 34 weeks of gestation. In the immature gastrointestinal tract, lactase and other disaccharidas are deficient until at least 34 weeks of gestation. One study in premature babies reported a benefit from the use of lactase-supplemented or lactose-reduced formulas, while the use of lactose-containing formulas and human milk did not appear to have short- or long-term harmful effects on infants and infants. Up to 20% of dietary lactose can reach the colon in newborns and young infants.

Due to the inadequate functional development of lactase, premature infants may not digest and absorb the main source of carbohydrate energy, lactose. The high osmotic load associated with indigestible lactose is one of the many possible causes of diarrhea and food intolerance in premature babies. As a result of diarrhea stools and small bowel damage, the already low functional activity of lactase will be further reduced affecting weight gain, while it takes up to 2 weeks for lactase activity to be restored.

Carlson et al showed that the addition of lactase to premature formula reduces the amount of lactose by 70%, with a negligible effect on osmolarity. Previous studies have found that premature infants fed a reduced lactose formula had a better weight gain rate than those who took 100% lactose formula. In two of these studies, weight gain improved despite eating fewer calories.

In the present study we intend to test whether the use of lactase to hydrolysis lactose in premature milk would result in better weight gain and improved dietary tolerance by taking the same calorie intake. This is a prospective, randomized controlled trial with caregivers and investigators responsible for outcome analysis and interpretation masked to treatment allocation to evaluate feeding tolerance and weight gain in preterm infants receiving either (1) human milk or preterm formula supplemented with lactase (intervention group) or (2) human milk or preterm formula without lactase supplementation (non-intervention group).

The study will be carried out at the Second Neonatal Clinic and Neonatal Intensive Care Unit of the Aristotle University of Thessaloniki, in premature newborns (gestational age [GA] 28-34 weeks) who will be hospitalized in the Neonatal Intensive Care Unit.

The study will enroll newborns (1) with a gestational duration of 28 to 34 weeks, (2) who receive ≥75% of their energy needs intestinally, (3) with the absence of severe congenital malformations or gastrointestinal diseases, including necrotizing enterocolitis (NEC) (4) without taking postnatal steroids or diuretics at the time of eligibility assessment. Small, suitable and large for newborns of gestational age will be eligible for the study.

Exclusion criteria will be neonates whose guardians refuse to participate in the study, neonates with congenital malformations or gastrointestinal diseases, and neonates receiving postnatal steroids or diuretics.

The participation of newborns in the study will take place after written consent of the parents after information.

Read the detailed description

Lactose, a disaccharide that includes the monosaccharides glucose and galactose, is the main carbohydrate found exclusively in mammalian milk. The absorption of lactose requires lactase activity to break the bond that binds the 2 monosaccharides. Lactase is found in the intestinal mucosa and is located at the ends of the villi, while it is a factor of maximum clinical importance in milk tolerance and in the occurrence of diarrheal disease.

Milk intolerance can be attributed to either lactose or protein content. Lactose intolerance may occur in infants and young children with acute diarrhoea, although its clinical significance is limited. Lactose intolerance symptoms are relatively common among older children and adolescents. However, associated intestinal damage is rarely observed. Lactose tolerance is a separate entity from cow's milk protein allergy, which is of immune etiology and can cause varying degrees of intestinal mucosal injury. Cow's milk protein intolerance is reported in 2% to 5% of infants within the first 1 to 3 months of life, usually subsides by the age of 1 year and is not the subject of this statement.

In more specific cases, the hydrogen breath test is the least invasive and most helpful test for diagnosing lactose malabsorption. The test is performed by administering a standardized amount of lactose (2 g/kg, up to a maximum of 25 g, equivalent to the amount of lactose in 2 glasses of milk) after fasting overnight and then measuring the amount of hydrogen in the exhaled air for a period of 2 to 3 hours. An increase (20 ppm) in hydrogen after about 60 minutes is indicative of lactose malabsorption. Factors that may produce false negative or false positive results include conditions affecting the intestinal flora (e.g., recent use of antimicrobial agents), lack of hydrogen-producing bacteria (10%-15% of the population), ingestion of a high-fiber diet before testing, bacterial overgrowth of the small intestine, or intestinal motility disorders.

In newborns and infants with diarrhea in whom lactose (or other carbohydrate) intolerance is suspected, the stool can be checked for carbohydrate malabsorption by testing the pH of the stool, which is reduced by carbohydrate malabsorption as a result of the formation of volatile fatty acids. It is noted that the pH of the stool is lower in infants compared to older children and adolescents due to the normal overload of lactose in their diet; which in turn helps to promote the growth of Lactobacillus species in the large intestine. Reducing substances can also be detected in the stool, such as reducing sugars that include lactose, glucose, fructose and galactose, but not sucrose. Because some patients may only absorb enough carbohydrates, such as lactose, to lower the pH of the stool but not increase the excretion of carbohydrates in the stool, the pH test is a more sensitive test for carbohydrate malabsorption.

Developmental lactase deficiency is defined as the relative lactase deficiency observed in premature newborns less than 34 weeks of gestation. In the immature gastrointestinal tract, lactase and other disaccharidesas are deficient until at least 34 weeks of gestation. One study in premature babies reported a benefit from the use of lactase-supplemented foods or lactose-reduced preparations. While the use of lactose-containing preparations and human milk does not appear to have short- or long-term harmful effects on newborns and infants. Up to 20% of dietary lactose can reach the colon in newborns and young infants. The metabolism of lactose by colon microbes lowers the pH of the stool, which has a beneficial effect, favoring certain organisms (e.g. Bifidobacterium and Lactobacillus species) instead of potential pathogens (Proteus, Escherichia coli and Klebsiella species) in young infants.

Lactase is detected for the first time in the fetus from the 10th week of gestation. At 28 to 34 weeks, lactase activity is only \~30% of that found at the end of pregnancy. At 35 to 38 weeks, it reaches 70% of the activity of the end months. Due to the inadequate functional development of lactase, premature infants may not digest and absorb the main source of carbohydrate energy, lactose. The high osmotic load associated with indigestible lactose is one of the many possible causes of diarrhea and food intolerance in premature babies. As a result of diarrhea stools and small bowel damage, the already low functional activity of lactase will be further reduced affecting weight gain, while it takes up to 2 weeks for lactase activity to be restored.

Lactose intolerance is often treated with soy proteins, protein hydrolysis products, low-lactose, or lactose-free formulas. However, these types do not meet the nutritional requirements for the development and development of premature newborns, which need human milk with a human milk booster or premature milk. Ideally, premature babies with lactose intolerance should take these hydrolyzed lactose foods. Carlson et al showed that the addition of lactase to premature formula reduces the amount of lactose by 70% after a 2-hour incubation period at room temperature, with negligible effect on osmolarity. Previous studies have found that premature infants fed a reduced lactose formula had a better weight gain rate than those who took 100% lactose formula. In two of these studies, weight gain improved despite eating fewer calories.

In the present study we intend to test whether the use of lactase to hydrolysis lactose in premature milk would result in better weight gain and improved dietary tolerance by taking the same calorie intake.

METHOD Study Population A prospective, randomized controlled trial with caregivers and investigators responsible for outcome analysis and interpretation masked to treatment allocation will be conducted to evaluate feeding tolerance and weight gain in preterm infants receiving either (1) human milk or preterm formula supplemented with lactase (intervention group) or (2) human milk or preterm formula without lactase supplementation (non-intervention group).

Study Day 1 will be the day on which intestinal feeding will provide ≥75% of the daily intake of caloric needs. The study will be terminated when the newborn reaches 36 weeks or is discharged from the unit, whichever comes first.

Inclusion criteria The study will enrol newborns (1) with a gestational duration of 28 to 34 weeks, (2) who receive ≥75% of their energy needs intestinally, (3) with the absence of severe congenital malformations or gastrointestinal diseases, including necrotizing enterocolitis (NEC) (4) without taking postnatal steroids or diuretics at the time of eligibility assessment. Small, suitable and large for newborns of gestational age will be eligible for the study.

Exclusion criteria Exclusion criteria will be neonates whose guardians refuse to participate in the study, neonates with congenital malformations or gastrointestinal diseases, and neonates receiving postnatal steroids or diuretics.

Feeding newborns The feeding of the newborns of the study will be in accordance with the usual practices of the clinic, i.e. the first choice will be breast milk, the second the human milk of the donor from the milk bank and the third choice the formula of premature newborns. Breast milk fortifiers will be added to breast milk according to the usual clinic practices, i.e. when the volume of milk administered exceeds 25 ml per meal.

Human milk is given an estimated caloric value of 68 kcal/100 mL, while premature formula is given 81 kcal/100 mL.

Randomization Guardians of newborns who meet the criteria for inclusion in the study will be approached to be informed about participation in the study. Newborns whose guardians consent to participate will be included in the study.

Newborns, after enrolment in the study, will be randomized to either the lactase group or the control group. The results of randomization will not be known to the principal investigator until after the study is completed.

Intervention Newborns in the lactase group will receive milk fortified with 2 drops of lactase/kg of body weight per meal. The enrichment of the milk with lactase drops will be carried out by the nurse on duty without it being known by the principal investigator to which group (lactase group or control group) each newborn belongs. Only a secondary researcher and the shift nurse will have access to neonatal randomization information.

The lactase drops that will be used in the study will be Delictase®. The supply of Delictase® lactase preparations will be carried out by Prime Biosciences, every 2 months at the study site.

Recording of results For all newborns in the study, perinatal and neonatal data will be recorded on computers anonymously by the researchers. Somatometric data (body weight, head circumference, body length) will be recorded at birth and per week until the completion of the study. Biochemical markers of homeostasis (protein, albumin, sodium, and potassium) will also be recorded according to the usual practices of neonatal hospitalization in the NICU. Caloric intake and type of food will be recorded daily The main outcome variable will be daily weight-gain velocity from study entry to study completion, calculated for each infant as the difference between body weight at study completion and body weight on study day one divided by the number of study days.

Secondary outcomes will include head circumference and length gain velocities. Other prespecified outcomes will include abdominal distension, emesis, bowel-movement frequency, and serum total protein, albumin, sodium, and potassium concentrations. Gastric residual volume and stool reducing substances were prespecified feeding-tolerance measures but were not incorporated into prospective data collection and therefore were not available for analysis. Feeding-tolerance outcomes will include abdominal distension, emesis, and bowel-movement frequency. Abdominal distension will be recorded as the occurrence of clinically apparent abdominal distension at any time during the study period. For emesis, weekly incidence will be defined as the proportion of infants experiencing at least one day with >2 episodes within 24 hours during the respective study week. Bowel-movement frequency will be recorded as the number of bowel movements per day.

Serum protein, albumin, sodium, and potassium concentrations will be obtained according to routine clinical practice and will be also recorded. Finally, any withdrawal from the study due to feeding intolerance or NEC will be recorded.

Statistical analysis According to previous studies, the main outcome of the study (weight gain, g/day) was used as the basis for calculating the sample size. A total of 100 newborns (50 newborns per group) allows the detection of a 33% increase in mean weight gain per day in the treatment group, with a strength of 0.80. The differences between the groups are considered statistically significant at the level of P \<.05.

Neonatal characteristics of the lactase and control group will be compared with the t-test in terms of continuous variables (caloric intake, weight gain, length, head circumference, gastric residual volume, daily number of vomiting episodes, daily stool count, and serum albumin, total protein, sodium, and potassium concentrations) or the Mann-Whitney test for variables with abnormal dispersion. The Pearson X2 or Fisher exact test will be used to compare the categorical variables (proportion of neonates in each group who developed food intolerance, had at least one episode of vomiting during the study, withdrew from the study due to medical condition or parental request, or experienced NEC) between the two groups.

Regression analysis will be used to check the correlation of weight gain with lactase administration or not, stratified for perinatal and neonatal factors with statistical significance.

Duration of the study Recruitment is expected to begin in August 2025 and be completed within 24 months.

03

Conditions studied

  • Prematurity

Keywords

  • Lactase
  • Prematurity
  • Human milk
  • Weight gain
  • Feeding intolerance
04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Neonates with a gestational duration of 28 to 34 weeks,
  • Neonates who receive ≥75% of their energy needs intestinally,
  • Neonates with the absence of severe congenital malformations or gastrointestinal diseases, including necrotizing enterocolitis (NEC),
  • Neonates without taking postnatal or diuretics at the time of eligibility assessment,
  • Neonates small, appropriate and large for gestational age

Exclusion criteria

Exclusion Criteria:

  • Neonates whose guardians refuse to participate in the study,
  • Neonates with congenital malformations or gastrointestinal diseases,
  • Neonates receiving postnatal or diuretics.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Lactase-Fortified Milk

    Newborns in the lactase group will receive milk fortified with 2 drops of lactase/kg of body weight per meal. The enrichment of the milk with lactase drops will be carried out by the nurse on duty without it being known by the principal investigator to which group (lactase group or control group) each newborn belongs. Only a secondary researcher and the shift nurse will have access to neonatal randomization information. The lactase drops that wiil be used in the study will be Delictase, an exogenous source of the lactase enzyme, which contains 126 Acid Lactase Units (ALU) of lactase per drop.The supply of Delictase® lactase preparations will be carried out by Prime Biosciences, every 2 months at the study site.

    Dietary Supplement: Lactase

  • No intervention
    Control

    The feeding of the newborns of the study will be in accordance with the usual practices of the clinic, i.e. the first choice will be breast milk, the second the human milk of the donor from the milk bank and the third choice the formula of premature newborns. Breast milk boosters will be added to breast milk according to the usual clinic practices, i.e. when the volume of milk administered exceeds 25 ml per meal. Human milk is given an estimated caloric value of 68 kcal/100 mL, while premature formula is given 81 kcal/100 mL.

Interventions

  • Dietary supplementLactase

    The lactase drops that will be used in the study will be Delictase®, an exogenous source of the lactase enzyme, which contains 126 Acid Lactase Units (ALU) of lactase per drop. The supply of Delictase® lactase preparations will be carried out by Prime Biosciences, every 2 months at the study site.

06

What researchers measure

Primary outcomes

  1. Weight-gain velocity

    The primary outcome will be mean daily weight-gain velocity from study entry to study completion, calculated for each infant as the difference between body weight at study completion and body weight on study day one divided by the number of study days. Unit of Measure: g/d

    Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.

Secondary outcomes

  1. Head circumference gain velocity

    Head circumference gain velocity from study entry to study completion will be calculated for each infant as the difference between head circumference at study completion and head circumference on study day one divided by the number of study weeks. Unit of Measure: cm/week

    Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.

  2. Length gain velocity

    Length gain velocity from study entry to study completion will be calculated for each infant as the difference between body length at study completion and body length on study day one divided by the number of study weeks. Unit of Measure: cm/week

    Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.

Other outcomes

  1. Occurrence of abdominal distension

    Occurrence of clinically apparent abdominal distension at any time during the study period. Unit of Measure: Participants

    Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.

  2. Weekly incidence of emesis

    Weekly incidence of emesis will be defined as the proportion of infants experiencing at least one day with more than 2 episodes of emesis within 24 hours during the respective study week. Unit of Measure: Percentage of participants

    Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.

  3. Bowel-movement frequency

    Bowel-movement frequency will be recorded as the number of bowel movements per day. Unit of Measure: bowel movements/day

    Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.

  4. Serum total protein concentration

    Serum total protein concentration obtained according to routine clinical practice during the study period. Unit of Measure: g/dL

    Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.

  5. Serum albumin concentration

    Serum albumin concentration obtained according to routine clinical practice during the study period.Unit of Measure: g/dL

    Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.

  6. Serum sodium concentration

    Serum sodium concentration obtained according to routine clinical practice during the study period. Unit of Measure: mmol/L

    Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.

  7. Serum potassium concentration

    Serum potassium concentration obtained according to routine clinical practice during the study period. Unit of Measure: mmol/L

    Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.

  8. Gastric residual volume

    Gastric residual volume was a prespecified feeding-tolerance measure but was not incorporated into prospective data collection and therefore was not available for analysis. Unit of Measure: mL

    Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.

  9. Stool reducing substances

    Stool reducing substances were a prespecified feeding-tolerance measure but were not incorporated into prospective data collection and therefore were not available for analysis. Unit of Measure: Not applicable

    Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.

07

Study locations

1 site
  • Papageorgiou General Hospital
    Thessaloniki, Greece
08

References and documents

Publications

  • Shulman RJ, Feste A, Ou C. Absorption of lactose, glucose polymers, or combination in premature infants. J Pediatr. 1995 Oct;127(4):626-31. doi: 10.1016/s0022-3476(95)70128-1. PubMed 7562290 ↗
  • Kien CL, McClead RE, Cordero L Jr. Effects of lactose intake on lactose digestion and colonic fermentation in preterm infants. J Pediatr. 1998 Sep;133(3):401-5. doi: 10.1016/s0022-3476(98)70278-1. PubMed 9738725 ↗
  • Kien CL, Liechty EA, Mullett MD. Effects of lactose intake on nutritional status in premature infants. J Pediatr. 1990 Mar;116(3):446-9. doi: 10.1016/s0022-3476(05)82842-2. No abstract available. PubMed 2308040 ↗
  • Griffin MP, Hansen JW. Can the elimination of lactose from formula improve feeding tolerance in premature infants? J Pediatr. 1999 Nov;135(5):587-92. doi: 10.1016/s0022-3476(99)70057-0. PubMed 10547247 ↗
  • Meetze WH, Valentine C, McGuigan JE, Conlon M, Sacks N, Neu J. Gastrointestinal priming prior to full enteral nutrition in very low birth weight infants. J Pediatr Gastroenterol Nutr. 1992 Aug;15(2):163-70. doi: 10.1097/00005176-199208000-00011. PubMed 1403464 ↗
  • Reis BB, Hall RT, Schanler RJ, Berseth CL, Chan G, Ernst JA, Lemons J, Adamkin D, Baggs G, O'Connor D. Enhanced growth of preterm infants fed a new powdered human milk fortifier: A randomized, controlled trial. Pediatrics. 2000 Sep;106(3):581-8. doi: 10.1542/peds.106.3.581. PubMed 10969106 ↗
  • Schanler RJ. The low-birth weight infant. In: Walker WA, Watkins JB, eds. Nutrition in pediatrics: basic science and clinical application. 2nd ed. Hamilton, Ontario, Canada: BC Decker Inc; 1996. p. 392-412.
  • American Academy of Pediatrics Com- mittee on Nutrition. Pediatric Nutrition Handbook. 4th ed. Elk Grove (IL): American Academy of Pediatrics; 1998. p. 69
  • Nutrition Committee of the Canadian Pediatric Society. Nutrient needs and feeding of preterm infants. Can Med Assoc J 1995;52:1756-85.
  • Sinden AA, Sutphen JL. Dietary treatment of lactose intolerance in infants and children. J Am Diet Assoc. 1991 Dec;91(12):1567-71. PubMed 1960350 ↗
  • Carlson SJ, Rogers RR, Lombard KA. Effect of a lactase preparation on lactose content and osmolality of preterm and term infant formulas. JPEN J Parenter Enteral Nutr. 1991 Sep-Oct;15(5):564-6. doi: 10.1177/0148607191015005564. PubMed 1942472 ↗
  • Lebenthal E, Lee PC, Heitlinger LA. Impact of development of the gastrointestinal tract on infant feeding. J Pediatr. 1983 Jan;102(1):1-9. doi: 10.1016/s0022-3476(83)80276-5. PubMed 6401326 ↗
  • Brady MS, Rickard KA, Fitzgerald JF, Lemons JA. Specialized formulas and feedings for infants with malabsorption or formula intolerance. J Am Diet Assoc. 1986 Feb;86(2):191-200. PubMed 3511129 ↗
  • Saavedra JM, Perman JA. Current concepts in lactose malabsorption and intolerance. Annu Rev Nutr. 1989;9:475-502. doi: 10.1146/annurev.nu.09.070189.002355. No abstract available. PubMed 2669882 ↗
  • Kien CL. Carbohydrates. In: Tsang RC, Lucas A, Uauy R, et al, eds. Nu- tritional needs of the preterm infant: scientific basis and practical guide- lines. Baltimore (MD): Williams and Wilkins; 1993. p. 47-63.
  • Groh-Wargo S. Gastrointestinal development. In: Groh-Wargo S, Thompson M, Hovasi Cox J, Hartline JV, editors. Nutritional care for high risk newborns. Chicago: Precept Press; 2000. p. 209-30.

Individual participant data

Plan to share: Yes — Deidentified data can be available upon reasonable request.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Aug 2026, 12 months.

Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's 12 months is below that.

Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Aug 2027 → Aug 2026 and completion Aug 2027 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 2, 2025
StartActual
Aug 27, 2025
Primary completionActual
Aug 31, 2026was Aug 2027
CompletionActual
Aug 31, 2026was Aug 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 7, 2026
Sites
1 site removed
Show 1 removed
  • Papageorgiou General Hospital · Thessaloniki, Greece
Oct 7, 2026
Primary completion
Aug 2027→Aug 31, 2026 (actual)
Oct 7, 2026
Study completion
Aug 2027→Aug 31, 2026 (actual)
Oct 7, 2026
Eligibility
Minimum age 1 Day→none; Maximum age 4 Weeks→none; Criteria revised in 2 updates
What changed on Oct 7, 2026
Inclusion criteria
  • EditedThe study will enrol newborns (1) with a gestational duration of 28 to 34 weeks, (2) who receive ≥75% of their energy needs intestinally, (3) with the absence of severe congenital malformations or gastrointestinal diseases, including necrotizing enterocolitis (NEC) (4) without taking postnatal steroids or diuretics at the time of eligibility assessment. Small, suitable and large for newborns of gestational age will be eligible for the study.
What changed on Oct 8, 2026
Inclusion criteria
  • RemovedThe study will enrol newborns (1) with a gestational duration of 28 to 34 weeks, (2) who receive ≥75% of their energy needs intestinally, (3) with the absence of severe congenital malformations or gastrointestinal diseases, including necrotizing enterocolitis (NEC) (4) without taking postnatal steroids or diuretics at the time of eligibility assessment. Small, suitable and large for newborns of gestational age will be eligible for the study.
  • AddedNeonates with a gestational duration of 28 to 34 weeks,
  • AddedNeonates who receive ≥75% of their energy needs intestinally,
  • AddedNeonates with the absence of severe congenital malformations or gastrointestinal diseases, including necrotizing enterocolitis (NEC),
  • AddedNeonates without taking postnatal steroids or diuretics at the time of eligibility assessment,
  • AddedNeonates small, appropriate and large for gestational age
Exclusion criteria
  • EditedExclusion criteria will be neonatesNeonates whose guardians refuse to participate in the study, neonates with congenital malformations or gastrointestinal diseases, and neonates receiving postnatal steroids or diuretics.
  • AddedNeonates with congenital malformations or gastrointestinal diseases,
  • AddedNeonates receiving postnatal steroids or diuretics.
across 2 updates, Oct 7, 2026 – Oct 8, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Weigh GainNow Weight-gain velocityTime frame: 2-4 weeks → From study entry until 36 weeks' PMA or discharge, whichever occurred first.
Oct 7, 2026
Secondary outcomes
2 edited, 9 added, 2 removed
What changed in the outcomes
  • EditedHead circumference gain velocityTime frame: 2-4 weeks → From study entry until 36 weeks' PMA or discharge, whichever occurred first.
  • ChangedBefore Body lengthNow Length gain velocityTime frame: 2-4 weeks → From study entry until 36 weeks' PMA or discharge, whichever occurred first.
  • Addedother outcomeOccurrence of abdominal distensionTime frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
  • Addedother outcomeWeekly incidence of emesisTime frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
  • Addedother outcomeBowel-movement frequencyTime frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
  • Addedother outcomeSerum total protein concentrationTime frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
  • Addedother outcomeSerum albumin concentrationTime frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
  • Addedother outcomeSerum sodium concentrationTime frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
  • Addedother outcomeSerum potassium concentrationTime frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
  • Addedother outcomeGastric residual volumeTime frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
  • Addedother outcomeStool reducing substancesTime frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
  • Removedother outcomeBiochemistryTime frame: 2-4 weeks
  • Removedother outcomeFeeding intoleranceTime frame: 2-4 weeks
Oct 7, 2026
Show all 2 updates
  1. Oct 8, 2026
    Eligibility 5 inclusion criteria added, 1 removed; 1 exclusion criterion edited, 2 added
    What changed in the criteria
    Inclusion criteria
    • RemovedThe study will enrol newborns (1) with a gestational duration of 28 to 34 weeks, (2) who receive ≥75% of their energy needs intestinally, (3) with the absence of severe congenital malformations or gastrointestinal diseases, including necrotizing enterocolitis (NEC) (4) without taking postnatal steroids or diuretics at the time of eligibility assessment. Small, suitable and large for newborns of gestational age will be eligible for the study.
    • AddedNeonates with a gestational duration of 28 to 34 weeks,
    • AddedNeonates who receive ≥75% of their energy needs intestinally,
    • AddedNeonates with the absence of severe congenital malformations or gastrointestinal diseases, including necrotizing enterocolitis (NEC),
    • AddedNeonates without taking postnatal steroids or diuretics at the time of eligibility assessment,
    • AddedNeonates small, appropriate and large for gestational age
    Exclusion criteria
    • EditedExclusion criteria will be neonatesNeonates whose guardians refuse to participate in the study, neonates with congenital malformations or gastrointestinal diseases, and neonates receiving postnatal steroids or diuretics.
    • AddedNeonates with congenital malformations or gastrointestinal diseases,
    • AddedNeonates receiving postnatal steroids or diuretics.
  2. Oct 7, 2026
    Recruiting→Completed
    1 site removed
    Show 1 removed
    • Papageorgiou General Hospital · Thessaloniki, Greece
    Primary completion Aug 2027→Aug 31, 2026 (now actual)
    Study completion Aug 2027→Aug 31, 2026 (now actual)
    Eligibility Minimum age 1 Day→none; Maximum age 4 Weeks→none; 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedThe study will enrol newborns (1) with a gestational duration of 28 to 34 weeks, (2) who receive ≥75% of their energy needs intestinally, (3) with the absence of severe congenital malformations or gastrointestinal diseases, including necrotizing enterocolitis (NEC) (4) without taking postnatal steroids or diuretics at the time of eligibility assessment. Small, suitable and large for newborns of gestational age will be eligible for the study.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Weigh GainNow Weight-gain velocityTime frame: 2-4 weeks → From study entry until 36 weeks' PMA or discharge, whichever occurred first.
    Secondary outcomes 2 edited, 9 added, 2 removed
    What changed in the outcomes
    • EditedHead circumference gain velocityTime frame: 2-4 weeks → From study entry until 36 weeks' PMA or discharge, whichever occurred first.
    • ChangedBefore Body lengthNow Length gain velocityTime frame: 2-4 weeks → From study entry until 36 weeks' PMA or discharge, whichever occurred first.
    • Addedother outcomeOccurrence of abdominal distensionTime frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
    • Addedother outcomeWeekly incidence of emesisTime frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
    • Addedother outcomeBowel-movement frequencyTime frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
    • Addedother outcomeSerum total protein concentrationTime frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
    • Addedother outcomeSerum albumin concentrationTime frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
    • Addedother outcomeSerum sodium concentrationTime frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
    • Addedother outcomeSerum potassium concentrationTime frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
    • Addedother outcomeGastric residual volumeTime frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
    • Addedother outcomeStool reducing substancesTime frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
    • Removedother outcomeBiochemistryTime frame: 2-4 weeks
    • Removedother outcomeFeeding intoleranceTime frame: 2-4 weeks
    + 8 other changes: identifiers, verification date, description, conditions, design details, arm descriptions, contact details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07150884
Responsible party
Dimitrios Rallis (Assistant Professor in Pediatrics and Neonatology, Aristotle University Of Thessaloniki) — Principal investigator
First posted
Sep 2, 2025
Start date
Aug 27, 2025
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026
Last update
Oct 8, 2026

Study contacts

Christos Tsakalidis
study director · Aristotle University Of Thessaloniki

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lactase

Start the discussion